Study Findings from Vanderbilt University School of Medicine Provide New Insights into Human Parainfluenza Virus (Functional and Structural Basis of Human Parainfluenza Virus Type 3 Neutralization With Human Monoclonal Antibodies).

A recent study conducted by Vanderbilt University School of Medicine has provided new insights into the Human Parainfluenza Virus (hPIV3) and its potential treatment. hPIV3 is a respiratory pathogen that can cause severe disease in older people and infants. The study found that naturally occurring human antibodies can neutralize hPIV3 by targeting specific proteins on the virus. These monoclonal antibodies have shown promise in protecting against infection in vitro and in vivo. While vaccines for hPIV3 are still in clinical trials, this research offers potential clinical utility for the treatment of the virus. [Extracted from the article]